Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine
MJ Hepburn, MG Kortepeter, PR Pittman, EF Boudreau… - Vaccine, 2006 - Elsevier
MJ Hepburn, MG Kortepeter, PR Pittman, EF Boudreau, JA Mangiafico, PA Buck, SL Norris…
Vaccine, 2006•ElsevierA retrospective review was conducted of yellow fever vaccination among laboratory workers
receiving annual serologic assessment to determine the initial and long-term response after
boosting. Patients were divided into three groups based on pre-vaccination serology: Group
1, 1: 10; Group 2, 1: 20–1: 40 and Group 3,> 1: 40. The percent with≥ four-fold increase in
titers after booster vaccination were: 78%(646/829, Group 1), 65%(79/121, Group 2) and
10%(8/79, Group 3)(p< 0.0001). The median times to titer failure (< 1: 40) were 798 days …
receiving annual serologic assessment to determine the initial and long-term response after
boosting. Patients were divided into three groups based on pre-vaccination serology: Group
1, 1: 10; Group 2, 1: 20–1: 40 and Group 3,> 1: 40. The percent with≥ four-fold increase in
titers after booster vaccination were: 78%(646/829, Group 1), 65%(79/121, Group 2) and
10%(8/79, Group 3)(p< 0.0001). The median times to titer failure (< 1: 40) were 798 days …
A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20–1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p<0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p<0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.
Elsevier